Article
Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Aug 2005
Shalli Kawan, Brown Iain, Heys Steven D, Schofield Andrew C
Abstract excerpt
Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin iso...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
